The development of antibiotic resistance during treatment is a threat to patients and their environment. Insight in the mechanisms of resistance development is important for appropriate therapy and infection control. Here, we describe how through the application of mass spectrometrybased proteomics, a novel beta-lactamase Axc was identified as an indicator of acquired carbapenem resistance in a clinical isolate of Achromobacter xylosoxidans. Comparative proteomic analysis of consecutively collected susceptible and resistant isolates from the same patient revealed that high Axc protein levels were only observed in the resistant isolate. Heterologous expression of Axc in Escherichia coli significantly increased the resistance towards carbapenems. Importantly, direct Axc mediated hydrolysis of imipenem was demonstrated using pH shift assays and 1 H-NMR, confirming Axc as a legitimate carbapenemase. Whole genome sequencing revealed that the susceptible and resistant isolates were remarkably similar. Together these findings provide a molecular context for the fast development of meropenem resistance in A. xylosoxidans during treatment and demonstrate the use of mass spectrometric techniques in identifying novel resistance determinants.
Results
Development of meropenem resistance in Achromobacter xylosoxidans during treatment. An antibiogram of a clinical isolate of Achromobacter xylosoxidans from a patient treated for pneumonia (see Methods for details about patient history and treatment) revealed a multi-resistant character, but it was susceptible to meropenem (Supplemental Table 1 ). Hence, meropenem treatment was initiated. During treatment, the patient developed a pneumothorax and died from septic shock 6 days later. An antibiogram of a blood culture from a sample taken one day before the patient's death revealed a meropenem-resistant A. xylosoxidans phenotype (Supplemental Table 1 ). Subsequently, pure cultures from the first and second clinical isolate were prepared (AchroS and AchroR, respectively ( Table 1) ). In line with the antibiogram analysis described above, Etests showed that both isolates were resistant to imipenem (MIC > 32 mg/L for both) but differed in their susceptibility towards meropenem (MIC of 0.0094 mg/L (first isolate, AchroS) and 2 mg/L (second isolate, AchroR), respectively). An in-house multiplex PCR assay (based on a published PCR) 23 failed to detect common carbapenemases (KPC, IMP, VIM, NDM and OXA-48, data not shown), suggesting that the change in resistance is not mediated by these enzymes. This finding prompted us to perform a comparative proteomic analysis of the two isolates to attempt to identify the meropenem resistance mechanism.
Comparative proteomic analysis shows differential levels of the beta-lactamase Axc. Protein extracts of the meropenem-susceptible and resistant A. xylosoxidans isolates (AchroS and AchroR) were first analysed by SDS-PAGE. Since no major visual differences were observed (Supplemental Fig. S1A ), all bands were excised and processed for a bottom-up LC-MS/MS proteomic analysis. In total, 2276 unique proteins were identified, of which 1519 proteins were common to both isolates, while 223 and 534 were only found in the susceptible and resistant isolates, respectively. For a semi-quantitative analysis, the spectra assigned to peptides belonging to a certain protein were counted and compared between the two different isolates (Supplemental Figs S1B and S2, Table S2 ). Of the uniquely observed proteins, most were proteins with low spectral counts (often single peptide identifications), likely resulting from sampling bias of low abundant proteins. One protein was observed with 102 spectra in the resistant isolate (AchroR) but none in the susceptible isolate (AchroS). This protein, hereafter called Axc (for Achromobacter xylosoxidans carbapenemase, GenBank ID: MF767301), is a putative PenP class A beta-lactamase (COG2367/pfam13354).
To confirm that Axc was highly abundant in the resistant isolate in comparison to the susceptible isolate, a second proteomic analysis was performed on whole cell protein extracts that were digested in-solution and analysed without any prior fractionation. Spectral count analysis resulted in a cumulative quantification of 1342 different proteins, of which 981 were found in both isolates, but 196 and 165 were uniquely quantified in the susceptible and resistant isolates, respectively. The spectral count plot reflects the high similarity of the two clinical isolates, with the vast majority of the proteins distributed along the diagonal (Fig. 1A , Table S2 analysis demonstrated that the sequence of axc was identical in both isolates (data not shown), indicating that the observed meropenem resistance was not likely caused by an alteration of protein function. A database search revealed that the axc gene is not present in all A. xylosoxidans strains ( Fig. 2A ). Like in our clinical isolates, axc is present in the NH44784-1996 strain (ENA assembly GCA_000967095.1) 24 but not in the strains NBRC 15126/ATCC 27061 (ENA assembly GCA_000508285.1) and C54 (ENA assembly GCA_000758265.1) for instance. In those strains that contain axc, the gene is located next to a putative LysR-type transcriptional regulator (Pfam 03466), hereafter axcR (for axc-associated regulator). Additional PCR and Sanger sequencing experiments verified that the intergenic regions between axc and axcR in AchroS and AchroR were identical. However, they differed at two positions with the intergenic region between axc and axcR in strain NH44784_1996 (Supplemental Fig. S3B ).
The results showed a high degree of similarity between the meropenem resistant and susceptible strain, raising the possibility that these two strains represented a clonal complex. To further explore the relatedness of both Table 1 ). Three other fully sequenced genomes of Achromobacter xylosoxidans were examined for the presence of axc; NH44784_1996 (ENA assembly GCA_000967095.1), C54 (ENA assembly GCA_000758265.1) and NBRC_15126/ATCC27061 (ENA assembly GCA_000508285.1). Only within the strain NH44784_1996 (used as a reference to search our proteomics data), axc and the putative regulator are also present. (B) Unrooted cladogram obtained for 176 class A beta-lactamases including Axc. The class A β-lactamase protein sequences of Gram negative bacteria were obtained by querying the refseq_protein database using Blastp (<1e-10, http:// blast.ncbi.nlm.nih.gov/blast/Blast.cgi) and a consensus β-lactamase-alignment 37 . Duplicate sequences and sequences causing a strong overrepresentation of branches produced in the tree were removed. Names of known carbapenames (orange) and names of identifier of branches 37 are indicated. Axc is indicated with a red dot. The closest homologue to Axc, a β-lactamase from R. saidenbachensis (WP_029709665), is also indicated.
SCientifiC REPORts | (2018) 8:8181 | DOI:10.1038/s41598-018-26079-z isolates, whole genome sequencing (WGS) analysis was performed. This showed that both patient isolates were highly similar, with only one single-nucleotide polymorphism (SNP) within the gene encoding AxyZ 25 . This SNP was confirmed by PCR and subsequent Sanger sequencing, ruling out the possibility that this was an artefact of the assembly procedure. Moreover, axc and its putative regulator axcR were found to be located in the same genomic region as in NH44784_1996 strain ( Fig. 2A) . Overall, the genome sequences suggest that both isolates are clonal, and that the meropenem resistance evolved within the same strain during the course of treatment.
To demonstrate how Axc is related to other class A beta-lactamases, we compared the Axc amino acid sequence with the sequence of another 176 representatives of this family using an alignment consensus based on a report by Walther-Rasmussen and Hoiby 26 . The resulting unrooted cladogram shows that Axc is most closely related to a class A beta-lactamase of Rhodoferax saidenbachensis (WP_029709665, Fig. 2B ). Only a limited number of class A beta-lactamases have activity towards carbapenems, but none of these cluster with the Axc sequence ( Fig. 2B ).
Functional characterisation of Axc. To establish whether Axc indeed has activity towards carbapenems,
Axc was expressed in a heterologous host and hydrolysis of carbapenems was measured indirectly and directly.
The E. coli C43 strain, suitable for the expression of toxic proteins 27 , is susceptible to carbapenems. We generated a derivative of C43 that allows for IPTG-dependent expression of a plasmid-based copy of axc (E. coli_Axc (JC107)). Susceptibility testing for imipenem and meropenem showed that the MICs for these carbapenems increased 8-fold, following induction of Axc expression ( Table 2 ). Though these levels were lower than for the positive control (KPC) for our assay, they were specific for Axc as the expression of an unrelated protein (PPEP-1) 28 did not lead to an increase in MIC values (Table 2) . Thus, expression of Axc is correlated to resistance towards carbapenems.
To directly demonstrate carbapenemase activity, hydrolysis of imipenem was monitored in vitro through colorimetric assays ( Fig. 3A ) and 1 H-NMR ( Fig. 3B ). Imipenem hydrolysis results in the formation of a carboxylic acid, and monitoring the accompanying pH drop colorimetrically is a well-established method for the detection of carbapenemase activity 29, 30 . Indeed, hydrolysis of imipenem was readily observed using KPC cells (without IPTG). Consistent with our previous results, imipenem hydrolysis was observed for E. coli cells harbouring the Axc expression plasmid (E. coli_Axc) grown in the presence, but not in the absence, of IPTG. As before, these results were specific for Axc, as induction of PPEP-1 expression (E.coli_control) did not result in imipenem hydrolysis (Fig. 3A) . In a parallel assay, 1 H-NMR was used to directly observe the opening (hydrolysis) of the lactam ring in imipenem (Fig. 3B ). The chemical shifts of the peaks change as a result of this hydrolysis, with the protons closest to the ring opening undergoing the largest change. The H-6 proton of imipenem generates an adequately resolved multiplet at 3.42 ppm that decreases in intensity upon hydrolysis. Concomitantly, the doublet generated by the protons of the methyl group (H-9) move upfield, resulting in a decrease of the doublet at 1.3 ppm. After 10 minutes incubation of bacterial cells with imipenem, hydrolysis of imipenem was observed with E. coli_Axc grown in the presence, but not in the absence, of IPTG. Hydrolysis was also apparent for KPC, but not for E. coli cells expressing PPEP-1 (E.coli_control)), even after long incubation times (10 h). Under these conditions, imipenem hydrolysis was also observed for samples with E. coli cells harbouring the Axc expression plasmid grown in absence of IPTG, due to leaky expression from the inducible promoter.
Taken together, our data establish that Axc has carbapenemase activity.
Discussion
In this paper we identified a new resistance mechanism that explains the difference in meropenem susceptibility of two clinical isolates of A. xylosoxidans that were collected during treatment. Using a combination of comparative proteomic analyses and functional assays, we have shown that the class A beta-lactamase Axc is highly abundant in the meropenem resistant isolate in comparison to the susceptible isolate and that Axc has carbapenemase activity. Detection of carbapenemases from sequence data is challenging. First, carbapenemases belong to different subgroups of beta-lactamases which have probably evolved by convergent evolution. Although sequence identities are moderate, most of the class A carbapenemases have a disulphide bridge between Cys-69 and Cys-238, but this is dispensable for activity against carbapenems 31 and our data show that Axc does not contain these residues. Next, some studies also revealed a mechanism where beta-lactam trapping, without actual degradation, can be involved in resistance towards carbapenems when levels are sufficiently high. In such cases, concomitant loss of porins is often observed 32, 33 . Thus, it is crucial to determine whether a beta-lactamase actually induces hydrolysis of carbapenems. Our NMR and pH-shift analyses data clearly demonstrate Axc-mediated opening of the beta-lactam ring in imipenem. Finally, many unexplained mechanisms of carbapenem resistance remain. For 34 . Though the prediction of the activity of a certain beta-lactamase against carbapenems is not straightforward, studies such as the present one highlight that mass spectrometry approaches can be used to gain insight in the mechanism of action and role of specific proteins in the observed phenotypes. We do not know whether the high level of Axc is the only mechanism conferring meropenem resistance to our isolate of A. xylosoxidans. When expressed from an inducible promoter, Axc confers moderate resistance to carbapenems to E. coli; MIC values compared to the KPC strain suggest that Axc has a lower efficiency than KPC, but may also indicate lower overall levels of expression. Differing efficiencies in carbapenemases are well documented, to the point where the activity of a specific class, such as OXA-48, is difficult to detect but of great clinical importance 35 . Full biochemical characterization of Axc, including kinetic experiments, is subject to further study. Such experiments, in combination with crystallography analysis, will provide more insight in the activity of Axc against different beta-lactams and could resolve the structural characteristics of the binding pocket which facilitates its activity towards carbapenems. We note, however, that two other changes in the antibiogram between the meropenem susceptible and resistant isolates involve beta-lactam antibiotics. Augmentin (amoxicillin/clavulanate) resistance changed from intermediate (8 mg/L) to resistant (>32 mg/L), and piperacilline/ tazobactam from susceptible (< = 4 mg/L) to intermediate resistance (8 mg/L). This suggests that Axc may have a broad substrate specificity and is insensitive to inhibition by clavulanate and tazobactam. Strikingly, both the meropenem-susceptible and meropenem-resistant isolates were resistant to imipenem (MIC values higher than the maximum concentration tested (32 mg/L)). This indicates that, notwithstanding the activity of Axc towards imipenem as presented here, imipenem resistance in the clinical isolates is not dependent on Axc. Differences in the sensitivities towards different carbapenems results from the chemical differences between the individual drugs 36 and are often linked to the differential permeability of the outer cell membrane 37, 38 .
The regulatory mechanism leading to higher levels of Axc expression are unclear. Sequence analyses showed that the meropenem susceptible and resistant A. xylosoxidans clinical isolates are highly similar, with no differences in the axc promotor and coding sequence, nor in its putative regulator AxcR and the axc-axcR intergenic region. The only SNP we identified is located in the gene encoding AxyZ, the TetR-type repressor of the axyXY-oprZ operon 25 . This leads to an amino acid substitution (V29G) in a region of AxyZ that is involved in DNA binding in other members of TetR family 39 . AxyX, AxyY and OprZ form an efflux pump of the resistance-nodulation division (RND) family and are predominantly found in aminoglycoside resistant Achromobacter species [40] [41] [42] . A recent paper showed higher expression levels of axyY in A. xylosoxidans strains containing AxyZ_Gly29, suggesting that this mutation leads to reduced repression of AxyZ 43 . Closer inspection of our proteomics data indicates that also AxyX and AxyY are more abundant in the resistant isolate (spectral counts of 62 vs 21 for AxyX and 10 vs 2 for AxyY in the results presented in Fig. 1 (see Table S2 )). However, the difference is not as pronounced as found for Axc and more accurate quantitative proteomics experiments have to be performed to validate these data.
Mutations in TetR-like repressors have been linked to differences in carbapenem resistance 44 . For example, a 162 bp deletion in axyZ has been identified in certain carbapenem resistant strains 45 . However, even though AxyZ_Gly29 leads to higher expression of axyY, resulting in higher MIC values for aminoglycosides, fluoroquinolones and tetracyclines, no correlation between axyY expression and meropenem resistance was observed 43 . In line with this observation, a deletion of axyY in several A. xylosoxidans strains is reported to result in only a modest increase in the susceptibility towards carbapenems 25 . Taken together, it is likely that AxyXY-OprZ per se contributes little if any to the meropenem resistance phenotype of our clinical isolate. Instead, our data show a critical role for Axc and suggest that axc expression is regulated by AxyZ. If this is indeed the case, we postulate that the increase in the meropenem MIC for the ACH-CF-911 V29G strain 43 is accompanied by increased Axc levels.
From the clinical perspective, the development of resistance to meropenem within days following meropenem treatment is remarkable. Previous longitudinal analyses of different A. xylosoxidans isolates from one patient have revealed large phenotypic and genetic differences, for example in the resistance towards different classes of antibiotics but they were generally performed over longer time periods 24, 44, 45 . Such changes are believed to be the result of adaptive evolution of the initial strain which infected the patient, but there is also evidence that genetically different strains of A. xylosoxidans can co-exist within the same chronically infected individual 46 . Though we cannot exclude a co-infection, it is likely that the mutation in axyZ in our case occurred during treatment.
Finally, from a diagnostic point of view, the presence of Axc in both the sensitive and resistant A. xylosoxidans isolates complicates straightforward detection by molecular methods in the future and warrants detection based on protein abundance levels. Even though more elaborate mass spectrometry-based platforms clearly have potential for the detection of resistance and virulence proteins 47, 48 , as also exemplified in our study, it will take more time and effort before they could find their way into the medical microbiology laboratory to complement the now well-established application of MALDI-ToF-MS for bacterial species identification.
Methods

Patient history. All procedures performed in studies involving human participants were in accordance with the ethical standards of LUMC Medical Ethical Committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.
A 65-year old patient, diagnosed with chronic lymphocytic leukemia in 1989, underwent a non-myeloablative stem cell transplantation in July 2014. The patient was discharged on July 25 th but readmitted on August 1 st with a mucositis-associated neutropenic fever and blood cultures positive for Gemella haemolysans. The patient was treated with cefuroxim intravenously but developed pneumonia one week later. Analysis of a sputum sample showed a microscopically and culture confirmed fungal infection and abundant growth of a Gram-negative bacterium. This bacterium was identified as A. xylosoxidans by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. The patient was treated with liposomal amphotericin B for the fungal infection, but this did not result in improvement of the patient's status. Due to clinical deterioration the patient received ceftazidim (3 dd 1 gram intravenously) between September 3 rd and 9 th to treat the ceftazidim sensitive A. xylosoxidans isolate. On September 10 th , the antibiogram (Supplemental Table 1 ), revealed a multi-resistant character for the A. xylosoxidans isolate, but it was susceptible to meropenem. Hence, meropenem treatment was initiated (4 dd 1 gram intravenously) on September 10 th . During treatment the patient developed a pneumothorax and died from septic shock 6 days later. Because of this, informed consent of the patient was not possible to obtain. We therefore anonymized all patient data and presented the data in such a form that it is not traceable to the patient.
Materials.
MilliQ water was obtained from a Q-Gard 2 system (Merck Millipore, Amsterdam the Netherlands). Acetonitrile of LC-MS grade was obtained from Biosolve (Valkenswaard, the Netherlands). Porcine trypsin was purchased from Promega (Madison, WI). If not indicated otherwise, chemicals were from Sigma Aldrich (St Louis, MN, USA).
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Pure cultures of the susceptible and resistant isolates (AchroS and AchroR, respectively (Table 1) ) were subjected to further susceptibility testing and used for the proteomic and genomic analyses. Etests (bioMérieux) were performed according to the recommendations from EUCAST (http://www.eucast.org/clinical_breakpoints/). EUCAST does not provide recommendations for the interpretation of MIC values or clinical breakpoints for Achromobacter xylosoxidans. Therefore, scoring was performed using locally developed protocols that are based on clinical breakpoints for other non-fermentative Gram-negative rods.
Mass spectrometry-based proteomics. Cells were grown in BHI (Oxoid, Basingstoke, UK). Cells were collected by centrifugation (4000 g, 5 min) from 1 mL cell culture and washed with phosphate-buffered saline (PBS, pH 7.4). Pellets were stored at −80 °C until further use.
Two different proteomics experiments were performed. For the first, cell extracts from A. xylosoxidans strains (AchroS and AchroR, Table 1 ) were prepared in LDS (Lithium dodecyl sulphate) sample buffer (Novex, Thermo Scientific) and put at 95 °C for 5 minutes for cell lysis and protein extraction. Proteins were separated on Novex precast 4-12% Bis-Tris gels (Thermo Scientific, Waltham, MA, USA) with MOPS (3-(N-morpholino)propanesulfonic acid) running buffer (Thermo Scientific). After overnight staining using a Colloidal Blue Staining Kit (Thermo Scientific), destained gel lanes were processed into 31 slices per lane. Gel pieces were sequentially washed with 25 mM ammonium bicarbonate and acetonitrile. Reduction and alkylation were performed with dithiothreitol (DTT, 10 mM, 30 minutes at 56 °C) and iodoacetamide (IAA, 55 mM, 20 min at room temperature) respectively. Following several washes with 25 mM ammonium bicarbonate and acetonitrile, bands were overnight digested with trypsin (12.5 ng/μl in 25 mM NH 4 HCO 3 ). Digest solutions were lyophilized and reconstituted in 0.5% trifluoroacetic acid (TFA). Nano-LC separation was carried out using a Ultimate 3000 RSLCnano System equipped with an Acclaim PepMap RSLC column (C18, 75 µm × 15 cm with 2 µm particles, Thermo Scientific) preceded by a 2 cm Acclaim PepMap100 guard column (Thermo Scientific). Peptide elution was performed by applying a mixture of solvents A and B with solvent A being 0.1% formic acid (FA) in water and solvent B 0.1% FA in 80% acetonitrile (ACN). Peptides were eluted from the column with a multi-step gradient from 5% to 55% solvent B in 55 minutes (0-5 min 5%B, then in 15 min to 20%B and finally in 25 min till 55%B), at a constant flow rate of 300 nl min −1 . MS analysis was performed employing a maXis Impact UHR-TOF-MS (Bruker Daltonics, Bremen, Germany) in data dependent MS/MS mode in the m/z 150-2200 range. The source settings were as follows: voltage 1500 V, dry gas 3.0 l.min −1 , temperature 150 °C. Ten ions were selected at a time, based on relative abundance and subjected to collision-induced-dissociation with helium as collision gas. A 1 minute dynamic exclusion window was applied for precursor selection. The precursor isolation window and collision energy were m/z dependent.
For the second proteomics approach, in-solution digests were prepared as described previously 47 . In short, following cell disruption proteins were solubilized in 50% trifluoroethanol (TFE). Subsequent reduction with DTT and alkylation with IAA were performed prior to overnight tryptic digestion. Samples were lyophilized and reconstituted in 0.5% TFA for injection. The nano-LC system and solvents were the same as in the above experiment, but using an Acclaim PepMap RSLC column (C18, 75 µm × 50 cm with 2 µm particles, Thermo Scientific) with a 2 cm Acclaim PepMap100 guard column (Thermo Scientific). Peptides were eluted from the column with a multi-step gradient from 5% to 55% of solvent B in 180 minutes (0-5 min 5%B, then in 65 min till 13%B, then in 90 minutes till 35%B and finally in 20 min till 55%B), at a constant flow rate of 300 nl min −1 . MS analysis was carried out as described above.
Mass spectrometry data export and spectral count analysis. Conversion of Bruker Impact files into mzXML format using CompassXport version 3.0.9, led to an initial total of 1,207,329 MS/MS and 444,565 MS/MS spectra, for the gel and total lysate based comparisons, respectively (in-solution total lysate digests were analysed twice and the data were merged). These spectra were searched using a concatenated forward and decoy strategy. The forward database was constructed from the 6386 unreviewed sequences from Uniprot for the organism A. xylosoxidans NH44784-1996 (November 2015) together with the cRAP contaminant sequences, as downloaded in January 2015. An in-house developed program, Decoy version V1.0.1-2-gfddc, that preserves homology, amino-acid frequency and peptide length distribution, was used with default flags to construct the decoy search space, which was concatenated to the forward sequences. The search against the resulting database was performed using Comet version 2014.02 rev.2, with precursor mass tolerance equal to 50 ppm and a fragment bin width of 0.05 Da, considering only fully tryptic digests with at most 2 missed cleavages. All cysteines were assumed carbamidomethylated, while methionine oxidation and N-terminal acetylation were regarded as variable modifications. The confidence of these results was assessed by means of Xinteract from the Trans Proteomics Pipeline suite version 4.8.0, retaining peptides longer than 6 amino acids and running in semi-parametric mode. A second in-house developed program, Pepxmltool version 2.5.1, was used to construct a protein quantification table based on spectral counting of only non-degenerate peptides (peptides mapping to a single protein) with corresponding q-value of at most 1%. Plots of the resistant versus susceptible quantifications of all proteins revealed for both methods a predominantly linear relationship, suggesting the applicability of an in-house developed program, Qntdiff version 0.1.1, to assign p-values to deviations from linear behaviour and provide lists of the most significantly differential protein expression levels between the two isolates. The programs Pepxmltool and Qntdiff are available from the authors on request.
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Whole genome sequencing and SNP calling. Paired-end multiplex libraries were created as previously described 50 . Sequencing was performed on an Illumina Hiseq 2000 platform (Illumina, San Diego, Ca, USA), with a read-length of 100 basepairs. High-throughput de novo assembly of sequenced genome was performed as previously described 51, 52 . The assemblies are then automatically annotated using PROKKA 53 with genus-specific databases from RefSeq 54 . To identify single nucleotide polymorphisms (SNPs), the Illumina sequence data of the meropenem-susceptible A. xylosoxidans isolate (AchroS) was mapped on the assembled genome of the meropenem-resistant isolate (AchroR) using SMALT software (http://smalt.sourceforge.net/), after which SNPs were determined as previously described 50 . PCR and heterologous expression of Axc. To corroborate the proteomics results and confirm results from the whole genome sequence analysis, the axc ORF, the axc-axcR intergenic region and part of the axyZ ORF were Sanger sequenced at a commercial provider (Macrogen, Amsterdam, the Netherlands). PCR products (for primers see Table 3 ) were sequenced using the same primers as those used for generating the product from genomic DNA isolated from the A. xylosoxidans isolates. We have submitted the Axc sequence to Genbank, ID MF767301.
To construct an E. coli strain expressing Axc with a C-terminal 6xHis-tag from an IPTG (isopropyl β-D-1-thiogalactopyranoside) inducible promoter, the axc open reading frame was amplified using primers Axfor2 and Axrev3 (Table 3) , using Accuzyme polymerase (GC Biotech, Alphen aan den Rijn, The Netherlands) and genomic DNA from A. xylosoxidans (AchroR) as a template. The amplified PCR product was digested using NdeI (Bioké, Leiden, The Netherlands) and XhoI (Roche, Almere, The Netherlands), and cloned into similarly digested pET-21b(+), yielding plasmid pET21B/Axc. The axc expression region was confirmed using Sanger sequencing. Expression of Axc-his6 was carried out in E. coli C43(DE3) 27 in Luria-Bertani broth (Affymetrix, Cleveland, OH, USA) with ampicillin (50 µg/mL) and 1 mM IPTG (GC Biotech, Alphen aan de Rijn, the Netherlands) for 3 hrs at 37 °C and verified by immunoblotting using anti-His antibody (Agilent Technologies, Santa Clara, CA, USA).
Susceptibility testing of E. coli expressing Axc. Minimal inhibitory concentration (MIC) values for
the carbapenems imipenem (Etest, BioMérieux) and meropenem (microbroth dilution) were established for E. coli C43/pET21B-Axc (strain JC107, Table 1 ) in the presence and absence of 1 mM IPTG. For imipenem, cells were grown overnight in LB broth at 37 °C in the presence of ampicillin (50 µg/mL). The overnight cultures were diluted 1:100 in LB broth with ampicillin and grown to mid logarithmic phase (OD 600nm ~ 0.5). Two hundred μl of bacterial culture was spread on LB-ampicillin (50 µg/mL) plates (with or without 1 mM IPTG) and an Imipenem Etest (BioMérieux) was applied. MIC values were determined after 24 h incubation at 37 °C. The meropenem MIC values were established by microbroth dilution. Bacterial cultures in logarithmic phase (OD 600nm ~ 0.5) were diluted into LB-ampicillin medium to an OD 600nm of 0.05 in the presence or absence of 1 mM IPTG and subsequently seeded in a 96-well plate. A two-fold serial dilution of meropenem (starting at 12.5 µg/mL) was made by adding equal amounts of meropenem (25 µg/mL) to the first row, from which a two-fold dilution series was made in the rest of the plate. Samples were investigated for growth by measuring the OD 600nm after 24 hrs incubation at 37 °C, while shaking. The MIC was the lowest concentration of meropenem at which no growth was observed. As controls for our assays, a carbapenem resistant Klebsiella pneumoniae clinical isolate (KPC; JC113) and an unrelated expression construct (JC108; which expresses PPEP-1 28 in an IPTG-dependent manner in the same E. coli C43 background, Table 2 ) were included.
Colorimetric imipenem hydrolysis assay. Overnight bacterial cultures were diluted 100 fold in LB-ampicillin (50 µg/mL) medium and grown to exponential growth phase at 37 °C while shaking. At the time of induction, the OD 600nm was determined, the cultures were split in two and 1 mM IPTG was added to one of the cultures, followed by a further incubation for 3 hrs at 37 °C while shaking. At T = 3 h, the OD 600nm was determined Table 3 . Primers used in this study. Axc: Achromobacter xylosoxidans carbapenemase. axcR: axc-associated regulator. axyZ: TetR-type repressor of the axyXY-oprZ operon 36 .
SCientifiC REPORts | (2018) 8:8181 | DOI:10.1038/s41598-018-26079-z and cells were harvested by centrifugation (4000 g, 5 min) and stored at −20 °C overnight. Cells were resuspended in water to yield equal densities based on measured OD 600nm values. Then, 7.5 µL of bacterial suspension was mixed with 25 µL of imipenem/phenol red/ZnSO 4 solution (3 mg/mL imipenem, 0.35% (wt/vol) phenol red, pH 7.8, 70 µM ZnSO 4 ) and incubated at 37 °C for 1 hr. Conversion of imipenem leads to a pH drop that can be visualized by the color change of the buffer from red to yellow 29 . To quantify this effect, the UV-Vis spectrum was determined with a Nanodrop ND1000 spectrophotometer (Thermo Scientific) and the ratio between the absorption peaks at 431 and 560 nm was taken as a measure of imipenem hydrolysis.
NMR spectroscopy of imipenem conversion. All proton nuclear magnetic resonance ( 1 H-NMR) exper-
iments were performed on a 600 MHz Bruker Avance II spectrometer (Bruker BioSpin, Karlsruhe, Germany) equipped with a 5-mm triple resonance inverse (TCI) cryogenic probe head with a Z-gradient system and automatic tuning and matching. All experiments were recorded at 310 K. Temperature calibration was done before each batch of measurements 55 . The duration of the π/2 pulses was automatically calibrated for each individual sample using a homonuclear-gated nutation experiment on the locked and shimmed samples after automatic tuning and matching of the probe head. The samples were prepared by adding 70 µL imipenem aqueous solution (5 mg/mL) to 280 µL milliQ water. This solution was mixed with 350 µL 75 mM phosphate buffer (pH 7.4) in water/deuterium oxide (80/20) containing 4.6 mM sodium 3-[trimethylsilyl] d4-propionate. Twenty µL of bacterial cell suspension were added and the sample was mixed. Samples were manually transferred into 5-mm SampleJet NMR tubes. The cell suspension samples were kept at 6 °C on a SampleJet sample changer while queued for acquisition. For water suppression, presaturation of the water resonance with an effective field of γB1 = 25 Hz was applied during the relaxation delay. A 1D-version of the NOESY (Nuclear Overhauser effect spectroscopy) experiment was performed with a relaxation delay of 4 seconds. A NOESY mixing time of 10 ms was used during which the water resonance was irradiated with the presaturation RF field. After applying 4 dummy scans, a total of 98,304 data points covering a spectral width of 18,029 Hz were collected using 16 scans. The Free Induction Decay was zero-filled to 131,072 complex data points, and an exponential window function was applied with a line broadening factor of 0.3 Hz before Fourier transformation. The spectra were automatically phased and baseline corrected.
Bioinformatic analysis. Comparison of Axc with other class A beta lactamases was performed by multi-
ple alignment using the Geneious 9.0 (Biomatters Ltd, Auckland, New Zealand) software algorithm for Global alignment with free end gaps, cost Matrix Blosum62. The tree was then built using Jukes-Cantor genetic distance model with the Neighbor Joining tree build method.
